Retatrutide 60mg

Retatrutide 60mg is a research-grade triple agonist peptide targeting the GLP-1, GIP, and glucagon receptors, supplied in a high-concentration 60mg vial for advanced metabolic research. Every batch is HPLC-tested and ships with a batch-specific third-party Certificate of Analysis (COA) confirming identity and 99%+ purity. For laboratory and research use only. Not for human consumption. This product is not a drug, supplement, food, or cosmetic and is not intended to diagnose, treat, cure, or prevent any disease.

Research Applications

Retatrutide is a leading subject in triple-incretin research. Laboratory and preclinical models use it to study simultaneous GLP-1, GIP, and glucagon receptor activation, energy expenditure, lipid metabolism, and comparative potency against single- and dual-agonist peptides. The 60mg presentation supports multi-arm and dose-ranging research designs.

Purity & Verification

Every lot is analyzed by reversed-phase HPLC and, where applicable, mass spectrometry to confirm compound identity and 99%+ purity. A batch-specific, third-party Certificate of Analysis (COA) is included in the product gallery so researchers can confirm purity and identity before use. Supplied as a lyophilized (freeze-dried) powder; store sealed, cool, dry, and protected from light, and reconstitute per standard laboratory handling. Fast, tracked shipping from within the United States.

Peptide Research & Literature

Retatrutide is studied in peer-reviewed clinical trial literature as a triple-hormone receptor agonist. Selected published literature includes:

• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine, 2023. PMID: 37366315
• Bajaj HS, et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026. PMID: 42250575

These citations are provided for research reference only and do not imply any claim about the effects of this product.

Frequently Asked Questions

What makes Retatrutide different from Tirzepatide?
Retatrutide is studied as a triple receptor agonist (GLP-1, GIP, and glucagon), whereas Tirzepatide acts on two receptors. Both are used only in laboratory research.

What purity is this Retatrutide?
HPLC-verified to 99%+ purity with a batch-specific third-party COA included in the gallery.

Is the 60mg vial better value than the 30mg?
The 60mg vial offers a lower per-milligram research cost for labs running larger or repeated studies.

Is this for human use?
No. It is sold exclusively for in-vitro and preclinical research and is not for human or animal consumption.

What documentation comes with each order?
Each order includes a batch-specific third-party Certificate of Analysis confirming HPLC purity and identity.

Is this the same compound referenced in the published research literature?
Yes. Retatrutide is the same triple GIP/GLP-1/glucagon receptor agonist studied in the peer-reviewed clinical trial literature cited above.

For laboratory and research use only. Not for human consumption. This product is not a drug, supplement, food, or cosmetic and is not intended to diagnose, treat, cure, or prevent any disease.